Klario® named semi-finalist in American Diabetes Association Innovation Challenge 2026
- Klario®, developed by Flow Health Science, has been selected as a semi-finalist in the American Diabetes Association (ADA) Innovation Challenge 2026.
- Flow Health Science will join ADA leadership, board members, and key opinion leaders in New Orleans to contribute to discussions on advancing hypoglycaemia care.
- Findings from a 12-week randomised study of 1,000+ hypoglycaemic episodes showed a 27% reduction in recurrent hypoglycaemia and faster cognitive recovery.
London, UK – Flow Health Science announced that Klario® has been selected as a semi-finalist in the American Diabetes Association (ADA) Innovation Challenge 2026, recognising emerging innovations with the potential to advance diabetes care.
The ADA Scientific Sessions, taking place June 5–8 in New Orleans, will convene global leaders across research, clinical care, and innovation. As part of this recognition, Flow Health Science will engage in discussions with ADA leadership, board members, and key opinion leaders, including at the ADA Leadership Reception — an invitation-only forum bringing together selected innovators and sector leaders.
For people living with type 1 diabetes, the impact of hypoglycaemia often extends beyond the immediate event.
Klario® is designed to support recovery during hypoglycaemic episodes beyond glucose restoration alone. In a 12-week randomised study analysing more than 1,000 real-world hypoglycaemic episodes, use of Klario® was associated with a 27% reduction in recurrent hypoglycaemia and significantly faster cognitive recovery compared to glucose-only approaches.
“I felt much sharper, much sooner… that foggy, wiped-out feeling that usually lasts for hours just wasn’t there in the same way.”
— Tim, neurologist, Type 1 diabetes
These findings contribute to a broader conversation within the diabetes community about expanding outcome measures beyond glucose metrics alone. While Time-in-Range remains an important clinical standard, it may not fully reflect the cognitive and functional burden that can persist after a hypoglycaemic episode.
“In range doesn’t mean back to normal. Continuous glucose monitoring shows where glucose levels are, but it doesn’t capture whether someone can think clearly, focus, or feel like themselves again after a hypo. That gap is where we believe the next advances in care need to happen.”
— Georgia Myers, CEO at Flow Health Science
At ADA 2026, Flow Health Science will use this opportunity to support ongoing dialogue on how recovery is defined — including the importance of cognitive recovery and returning to normal daily function. This reflects a wider shift toward approaches that consider both physiological and lived experience outcomes in hypoglycaemia care.
Further information on Klario® and its clinical evidence is available here.
Klario®: A Novel Approach to Hypoglycaemia Management
Hypoglycemia represents a critical therapeutic challenge in diabetes management: people with T1D may experience 100–200 treatment-related episodes annually. Current recommended therapeutic interventions using glucose-only treatments frequently result in suboptimal outcomes, including rapid glucose fluctuations, persistent neuroglycopenic symptoms, and fear-driven non-adherence to medication.
Klario, a novel multi-substrate energy formulation combining glucose with BHB, was designed to achieve more complete recovery from hypoglycemia. In line with medical guidelines, Klario delivers 15 grams of fast-acting carbs to raise blood glucose quickly, while also raising BHB levels acutely. This combination formula improves glycemic control in the immediate post-treatment period and provides rapid, sustained neuroglycopenic recovery.
For more information about Klario, please visit myklario.com.
About Flow Health Science
Flow Health Science is dedicated to transforming health outcomes through trusted, clinically-proven functional foods. Grounded in advanced metabolic science, our research and pipeline targets diabetes management, fatigue, hormone imbalances, and broader metabolic dysfunction.
Media Contact: Tara Lumley, Chief Strategy & Business Officer — press@flowhealthscience.com
Source: Flow Health Science